title: Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects.
abstract: Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger the immunogenic demise of cancer cells, an effect that most likely contributes to their clinical anticancer activity.
authors.affiliation: INSERM; U848; Villejuif, France ; Institut Gustave Roussy; Villejuif, France ; Université Paris Sud/Paris XI; Le Kremlin Bicêtre, France.
authors.forename: Oliver
authors.initials: O
authors.lastname: Kepp
authors.forename: Laurie
authors.initials: L
authors.lastname: Menger
authors.forename: Erika
authors.initials: E
authors.lastname: Vacchelli
authors.forename: Sandy
authors.initials: S
authors.lastname: Adjemian
authors.forename: Isabelle
authors.initials: I
authors.lastname: Martins
authors.forename: Yuting
authors.initials: Y
authors.lastname: Ma
authors.forename: Abdul Qader
authors.initials: AQ
authors.lastname: Sukkurwala
authors.forename: Mickaël
authors.initials: M
authors.lastname: Michaud
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Galluzzi
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
authors.forename: Guido
authors.initials: G
authors.lastname: Kroemer